Cidofovir for Cats: How It Works Against Feline Herpesvirus

Cidofovir is an antiviral drug used topically in cats to treat ocular disease caused by feline herpesvirus type 1 (FHV-1), the most common infectious cause of eye problems in cats. Applied as a 0.5% eye drop, it has shown the ability to reduce viral shedding and ease clinical signs in controlled studies, and its twice-daily dosing schedule makes it more practical than older alternatives that require dosing five or six times a day. The drug is not without caveats, though, and its place among the growing list of feline antivirals deserves a closer look.

Why Cats Need an Antiviral Eye Drop in the First Place

FHV-1 is extremely widespread in cats. Most cats are exposed as kittens, and once infected, the virus sets up lifelong latency in nerve tissue. Stress, illness, or immune suppression can trigger reactivation, leading to flare-ups of conjunctivitis, corneal ulcers, or the chronic, sticky eye discharge that cat owners know all too well. In shelters and catteries, where stress is high and cats are packed together, FHV-1 spreads fast and hits hard, especially in young kittens whose immune systems are still developing.

The eye is the primary battleground. FHV-1 replicates in the cells lining the cornea and conjunctiva, causing inflammation, ulceration, and sometimes permanent scarring. Severe cases in kittens can destroy an eye entirely. Because FHV-1 is a DNA virus, the same broad class of antiviral drugs used against human herpesviruses can, in principle, target it. The challenge has been finding an antiviral that works well enough against FHV-1 specifically, is safe for feline eyes, and is practical for owners to administer.

How Cidofovir Works Against FHV-1

Cidofovir belongs to a class of antivirals called nucleotide analogues. It mimics one of the building blocks the virus uses to copy its DNA, but once incorporated into the growing viral DNA chain, it jams the machinery and stops replication. What makes cidofovir distinctive is that it does not need to be activated by a virus-specific enzyme first. Many older antivirals, like acyclovir, depend on a viral enzyme called thymidine kinase to convert them into their active form. FHV-1’s version of that enzyme is not particularly efficient at activating acyclovir, which is one reason acyclovir performs poorly against feline herpesvirus. Cidofovir bypasses that bottleneck because it only requires enzymes already present in the cat’s own cells to become active.

This mechanism also has a practical payoff: cidofovir has a long intracellular half-life. Once the drug gets inside a cell, its active form sticks around for an extended period, which is why twice-daily dosing is enough. Older topical antivirals for FHV-1, such as idoxuridine and trifluridine, need to be applied five to six times a day because they are cleared from the eye surface quickly. For a cat that already hates having drops put in its eyes, cutting the dosing frequency to twice daily is a significant quality-of-life improvement for both the cat and the owner.

What the Clinical Evidence Shows

The foundational study on cidofovir for feline eyes was an experimentally controlled trial in which cats were deliberately infected with FHV-1, then treated with either 0.5% cidofovir drops twice daily or a placebo, starting on the fourth day after infection. Over the ten-day treatment period, cats receiving cidofovir had significantly lower clinical disease scores and shed significantly less virus from their eyes compared to the control group.¹ This was the study that established the 0.5% concentration and twice-daily regimen as the standard protocol veterinarians still use today.

A more recent shelter-based study looked at cidofovir alongside famciclovir and ganciclovir in cats with naturally occurring FHV-1 eye disease. Cidofovir significantly decreased viral load between the first and eighth day of treatment compared with placebo, and cats treated with it also gained more weight, a useful proxy for overall well-being in sick shelter kittens.² That weight-gain finding matters because FHV-1 often causes upper respiratory signs that make kittens reluctant to eat, and a drug that helps them recover appetite faster can be the difference between thriving and fading in a shelter environment.

Despite these encouraging results, the overall evidence base for FHV-1 antivirals remains thin. A review of ocular FHV-1 treatment noted that few antiviral drugs have been evaluated in large, masked, controlled clinical trials, and that therapeutic decisions are often based on lab studies, case reports, and clinical experience rather than robust randomized data.³ Cidofovir is actually one of the better-studied options, which says more about how understudied the field is than about how ironclad the cidofovir data are.

How Cidofovir Compares to Other Antivirals

In lab testing against FHV-1 grown in cell culture, cidofovir is effective but not the most potent option. An in vitro study comparing six antivirals found that idoxuridine and ganciclovir were roughly twice as potent as cidofovir and penciclovir at inhibiting FHV-1 replication, while acyclovir and foscarnet were considerably weaker.⁴ Based purely on potency numbers, idoxuridine and ganciclovir look like better choices.

But in vitro potency does not tell the whole story. Idoxuridine is potent in a dish, but it has to be applied to the eye five or more times daily because it is cleared rapidly, making owner compliance a real problem. Ganciclovir, available commercially as a 0.15% ophthalmic gel, is gaining popularity and has the advantage of being a manufactured product rather than a compounded one, but it also requires more frequent dosing than cidofovir. The practical advantage of cidofovir’s twice-daily schedule can outweigh a modest potency gap, especially for cats that are difficult to medicate or in multi-cat environments where staff time is limited.

Famciclovir is an oral antiviral sometimes used alongside or instead of topical treatment. It can be given by mouth, which avoids the eye-drop struggle entirely, but it has its own complications: the dose needed in cats is relatively high, the tablets taste bitter, and the drug’s metabolism in cats is slower and more variable than in humans. Some veterinarians use oral famciclovir in combination with topical cidofovir for severe cases, though formal evidence for the benefit of that combination over either drug alone is limited.

Side Effects and Local Toxicity

In human medicine, cidofovir given intravenously is associated with serious kidney toxicity, which understandably makes some owners nervous when they hear the drug name. The topical ophthalmic version used in cats, however, delivers a tiny dose directly to the eye surface, and systemic absorption is minimal. Kidney damage has not been a documented concern with topical use in cats.

Local side effects are another matter. A three-year retrospective study of 140 cats treated with topical 0.5% cidofovir found that about 4% developed a suspected local toxic reaction.⁵ The affected cats showed a distinctive pattern: persistent squinting, eye discharge, redness, swelling of the conjunctiva, and a striking rapidly progressive darkening (melanosis) of the conjunctival tissue. When retested, those cats came back negative for FHV-1, meaning the signs were a drug reaction rather than ongoing infection. Conjunctival cell samples showed a mix of eosinophilic and neutrophilic inflammation with heavily pigmented epithelial cells.

The reassuring part is that the reaction resolved in all affected cats within about three weeks of stopping the medication. The median duration of treatment before toxicity appeared was 32 days, with a range of 23 to 62 days.⁶ This suggests that short courses of cidofovir are less likely to trigger the reaction than prolonged use. If your cat is on cidofovir for more than a few weeks and the eyes seem to be getting worse rather than better, or if you notice new darkening of the tissue around the eye, that is worth a prompt conversation with your veterinarian. The fix is straightforward: stop the drug and let the eyes recover.

Compounding, Storage, and Getting the Drops

One important practical detail: cidofovir eye drops for cats are not a commercially manufactured product you can pick up at a pharmacy. Cidofovir is approved for human use as an intravenous formulation (brand name Vistide), and the ophthalmic 0.5% solution used in cats has to be prepared by a compounding pharmacy. This means your veterinarian writes a prescription, a compounding pharmacy mixes the solution, and it gets shipped to you or the clinic. The process adds time and cost compared to grabbing a tube of ganciclovir gel off the shelf.

The good news on the stability front is that 0.5% cidofovir holds up well over time. Testing has shown that the solution retains its antiviral activity for up to six months when stored in either glass or plastic containers at refrigerator temperature, frozen, or deep-frozen.⁷ In practice, most compounding pharmacies assign a shorter beyond-use date out of regulatory caution, but the underlying stability data mean you do not need to worry about the drug losing its punch if it sits in your refrigerator for a few weeks before you use it up. Keeping it refrigerated is the standard recommendation.

Cost varies by pharmacy and region, but compounded cidofovir tends to be moderately expensive. A typical bottle might run anywhere from $50 to over $100, depending on the compounder and the volume prepared. Because FHV-1 flare-ups can be recurrent, some owners end up ordering the medication multiple times a year. The stability data at least mean that if your vet prescribes a larger volume, you can store the excess safely for later use.

Antiviral Resistance

Whenever an antiviral is used repeatedly, the worry about drug resistance comes up. If the virus mutates in the genes that the drug targets, the drug can stop working. A surveillance study specifically looked for resistance-associated mutations in FHV-1 from cats that had been treated with antiviral medications and found no variants in the key viral genes (UL23, UL30, and UL42) that would indicate developing resistance.⁸ That is encouraging, but it is a single study with a limited sample. Human herpesviruses do develop antiviral resistance over time, particularly in immunocompromised patients who receive prolonged courses of treatment, so it would be premature to say resistance is not a concern at all. It just has not been detected yet in the feline context.

From a practical standpoint, this means there is no current evidence that a cat’s FHV-1 will “get used to” cidofovir after repeated courses. If the drug worked well for a previous flare-up, it is reasonable to expect it will work again the next time. But if a cat with confirmed FHV-1 is not responding to cidofovir, the vet should consider whether the diagnosis is correct, whether compliance has been adequate, or whether a different antiviral or additional treatment is warranted, rather than simply assuming resistance.

When Cidofovir Makes Sense and When It Does Not

Cidofovir is strongest as a choice when the primary problem is active FHV-1 replication on the eye surface, meaning acute conjunctivitis or dendritic corneal ulcers in a cat with confirmed or strongly suspected herpesvirus. Its twice-daily dosing makes it especially appealing for cats that are hard to medicate, for multi-cat households where medicating several cats at once is a logistical challenge, and for shelters where staff have limited time per animal.

It is less clearly the right pick for chronic stromal keratitis or eosinophilic keratitis, conditions where the damage to the cornea is driven more by the cat’s immune response than by active viral replication. In those cases, veterinary ophthalmologists often use immunomodulatory drugs alongside or instead of antivirals. Cidofovir can still play a role in keeping viral load down while the immune-mediated inflammation is managed separately, but it should not be expected to resolve the problem on its own.

Cats with very mild, self-limiting conjunctivitis that clears up in a few days may not need antiviral treatment at all. FHV-1 flare-ups, like cold sores in people, sometimes resolve without medication. The decision to treat usually depends on severity, how quickly the cat is deteriorating, whether the cornea is involved, and whether the cat lives in a setting where spreading virus to other cats is a concern.

What Owners Often Get Wrong

A common misconception is that antiviral treatment will “cure” FHV-1 and prevent future flare-ups. Cidofovir, like all current antivirals for herpesvirus, suppresses active viral replication. It does not eliminate the latent virus hiding in nerve ganglia, and it does not prevent reactivation. Once treatment stops, the virus remains dormant in the cat’s body, ready to flare up the next time the cat is stressed or immunosuppressed. Owners who understand this are less likely to feel frustrated when the eye problems return months later.

Another point of confusion involves the name itself. Some owners research cidofovir and find alarming information about nephrotoxicity from the intravenous human formulation. The doses involved in IV cidofovir for serious human infections like CMV retinitis are orders of magnitude larger than what a cat’s eye absorbs from a topical drop. The toxicity profile of the eye drop in cats is a local one, limited to the eye, and systemic toxicity has not been a reported clinical problem with topical use.

Finally, owners sometimes assume that because a compounding pharmacy makes the drops rather than a pharmaceutical company, the product is somehow less reliable. Compounded medications do carry slightly more variability than mass-manufactured products, but the stability data for cidofovir are solid, and reputable compounding pharmacies follow strict quality-control protocols.⁹ The bigger concern with compounding is ensuring the pharmacy you use is accredited and experienced in ophthalmic preparations, since sterility matters a great deal for anything going into an eye.

Lysine Supplements and Cidofovir

Many cat owners encounter recommendations for L-lysine supplements as a way to manage FHV-1. The theory is that lysine competes with another amino acid, arginine, which the virus needs to replicate. For years, lysine was one of the most commonly recommended supplements for cats with herpesvirus. However, the evidence for lysine actually reducing FHV-1 flare-ups or severity has been repeatedly called into question. Multiple studies and reviews have failed to find consistent benefit, and some researchers have argued that supplemental lysine could theoretically make things worse by disrupting amino acid balance.

Where this intersects with cidofovir is that owners sometimes wonder whether lysine can replace antiviral drugs or whether combining the two gives better results. There is no controlled evidence that lysine adds benefit on top of antiviral therapy. If your cat has active eye disease severe enough to warrant cidofovir, lysine is unlikely to be an adequate substitute. Some veterinarians still recommend it as a low-risk addition, while others have stopped recommending it entirely based on the current evidence. Either way, it is not a substitute for a proven antiviral when the eyes are actively inflamed or ulcerated.